financetom
Business
financetom
/
Business
/
RioCan REIT Recorded Improved Earnings For Q4 and Lifted Monthly Distribution To Demonstrate Confidence In Its Core Business
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
RioCan REIT Recorded Improved Earnings For Q4 and Lifted Monthly Distribution To Demonstrate Confidence In Its Core Business
Feb 19, 2025 4:52 AM

07:24 AM EST, 02/19/2025 (MT Newswires) -- RioCan REIT (REI-UN.TO) overnight Tuesday reported improved funds from operations for the fourth quarter and increased its distribution for the fourth consecutive year to demonstrate confidence in its core business.

It reported Q4 FFO adjusted per unit diluted of $0.47 versus $0.44, and FFO per unit diluted of $0.45 versus $0.44, and also net income per unit diluted of $0.42 versus a loss of $0.39.

Among highlights, it said high demand locations generated new leasing spreads of 36.7% for 2024; blended leasing spreads of 18.7%. It cited record-breaking committed occupancy at 98.0%; retail committed occupancy at high water mark of 98.7%.

The company also cited 98% completion of the 372 expected Q4 condominium and townhouse interim closings to date; and added Adjusted Debt to Adjusted EBITDA improved to 8.98x from 9.28x at the end of the prior year.

On the distribution increase and outlook, RioCan's Board of Trustees approved a 4.3% increase to the monthly distribution to Unitholders from $0.0925 to $0.0965 per unit commencing with the February 2025 distribution, payable on March 7, 2025 to Unitholders of record as at February 28, 2025. This brings RioCan's annualized distribution to $1.16 per unit marking its fourth consecutive annual distribution increase.

Based on its FFO guidance for 2025, RioCan expects to maintain a payout ratio within its long-term target range of 55%-65%.

"RioCan had another exceptional year, continuing its trend of achieving its operational and financial objectives, reaching record occupancy and leasing spreads", said Jonathan Gitlin, President and CEO. "RioCan is well positioned to capitalize on the favourable retail real estate fundamentals in the under supplied Canadian market. Our recent Unit buybacks and the Board of Trustees' decision to increase our distribution for the fourth consecutive year demonstrate confidence in our core business and our team's ability to maximize asset value while strategically managing capital."

RioCan was up $0.11 at $18.88 yesterday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Aurora Cannabis Q2 revenue misses estimates despite 15% medical cannabis growth
Aurora Cannabis Q2 revenue misses estimates despite 15% medical cannabis growth
Nov 5, 2025
Overview * Aurora fiscal Q2 2026 revenue misses analyst expectations despite 15% growth in medical cannabis * Adjusted EBITDA for fiscal Q2 2026 grows 52% to C$15.4 mln * Company maintains strong balance sheet with C$141.9 mln cash, debt-free cannabis business Outlook * Aurora expects Q3 2026 net revenue to grow, driven by 8%-12% increase in Global Medical Cannabis *...
Recursion Pharmaceuticals Q3 Loss Widens, Revenue Falls
Recursion Pharmaceuticals Q3 Loss Widens, Revenue Falls
Nov 5, 2025
07:13 AM EST, 11/05/2025 (MT Newswires) -- Recursion Pharmaceuticals ( RXRX ) reported a Q3 loss Wednesday of $0.36 per diluted share, widening from a loss of $0.34 a year earlier. Analysts polled by FactSet expected a loss of $0.38. Revenue for the quarter ended Sept. 30 was $5.2 million, down from $26.1 million a year earlier. Analysts surveyed by...
MoonLake Immunotherapeutics' Q3 net loss widens
MoonLake Immunotherapeutics' Q3 net loss widens
Nov 5, 2025
Overview * MoonLake reports Q3 net loss of $70.7 mln, EPS at -$1.10 * Company ends Q3 with $380.5 mln in cash, providing runway into H2 2027 * R&D expenses rise due to clinical trials, including sonelokimab trials Outlook * Company expects cash reserves to fund operations into H2 2027 * MoonLake plans Phase 3 PPP trial initiation in Q3...
Anika beats Q3 revenue estimates, maintains guidance
Anika beats Q3 revenue estimates, maintains guidance
Nov 5, 2025
Overview * Anika Q3 revenue decreases 6% yr/yr to $27.8 mln, beating analyst expectations * Commercial Channel revenue up 22%, driven by Integrity and international OA growth * Company starts $15 mln share repurchase, reaffirming fiscal 2025 guidance Outlook * Anika maintains 2025 Commercial Channel revenue guidance at $47 to $49.5 mln * Anika maintains 2025 OEM Channel revenue guidance...
Copyright 2023-2026 - www.financetom.com All Rights Reserved